Tab Application Banner
  • Users Online: 503
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
REVIEW ARTICLE
Year : 2020  |  Volume : 15  |  Issue : 3  |  Page : 207-216

Autoinflammatory diseases: Emerging phenotypes


1 Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Paediatrics and Chief, Allergy Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Paediatrics, Paediatric Allergy and Immunology Unit, Advanced Paediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Date of Web Publication3-Sep-2020

Correspondence Address:
Dr. Amit Rawat
Department of Paediatrics, Paediatric Allergy and Immunology Unit, Advanced Paediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_31_20

Rights and Permissions
  Abstract 


Autoinflammatory diseases (AIDs) are a heterogeneous group of genetically inherited disorders involving genes regulating innate immune response. The genetic basis of several AIDs has been characterized and many new syndromes have been identified in the past few years. This review focuses on some of the common AIDs encountered in clinical practice.

Keywords: Blau syndrome, coatomer-associated protein alpha, deficiency of adenosine deaminase 2, infammasomopathies, interferonopathies, periodic fevers, STING-associated vasculopathy with onset in infancy


How to cite this article:
Anjani G, Singh S, Rawat A. Autoinflammatory diseases: Emerging phenotypes. Indian J Rheumatol 2020;15:207-16

How to cite this URL:
Anjani G, Singh S, Rawat A. Autoinflammatory diseases: Emerging phenotypes. Indian J Rheumatol [serial online] 2020 [cited 2020 Sep 24];15:207-16. Available from: http://www.indianjrheumatol.com/text.asp?2020/15/3/207/282826




  Introduction Top


Autoinflammatory diseases (AIDs) are a set of clinically distinct disorders with a heterogeneous clinical spectrum that may include repeated episodes of recurrent/persistent fever, mucocutaneous lesions, serositis, uveitis, and osteoarticular involvement. These conditions are characterized by the activation of innate immune cells (especially neutrophils and macrophages), resulting in self-directed inflammation and target tissue damage.[1] These episodes of systemic inflammation are often unprovoked. Unlike autoimmune diseases, AIDs generally do not have antigen-specific T-cells and B-cells or high-titer autoantibodies.


  Search Strategy Top


We searched PubMed engine on November 1, 2019 using the search terms “AID” and “autoinflammatory syndromes.” Of a total of 4751 articles, 43 articles which described various AIDs were selected with the consensus of the authors and reviewed. Based on these articles, the manuscript was prepared including an opinion of authors wherever deemed necessary.


  History Top


The first AID identified was familial  Mediterranean fever More Details (FMF) and its genetic defect was elucidated in 1997.[2] The term “AID” was first proposed by McDermott et al. in 1999 with the discovery of geneTNFRSF1A causing the tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).[3] Since that time, several new AIDs have been identified [Table 1].
Table 1: AIDs and their clinical correlates

Click here to view


Over the past two decades, there have been several major advances in our understanding of these conditions. While most of the AIDs are monogenic (e.g., FMF, cryopyrin-associated periodic syndrome [CAPS], TRAPS), some disorders (e.g., Behcet's disease, systemic juvenile idiopathic arthritis) are probably polygenic.

Most AIDs have well-defined immune defects and represent a continuum between primary immunodeficiency disorders and rheumatological disorders. Further, several monogenic forms of AIDs have a clinical presentation that can mimic some common rheumatological disorders [Table 2]. It is, therefore, important for all rheumatologists to be familiar with these conditions.
Table 2: Monogenic autoinflammatory diseases that can mimic the clinical presentation of common rheumatological disorders

Click here to view


While the clinical phenotype of several AIDs (e.g., Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA), Blau syndrome, TRAPS) is well recognized, genetic diagnosis is often necessary to confirm the diagnosis because of heterogeneity in clinical presentations – a distinct hallmark of AIDs.


  Pathophysiology Top


The final common abnormality in the pathogenesis of AIDs is enhanced production and release of proinflammatory cytokines. Common mechanisms[43] [Figure 1] involved in the pathogenesis of AIDs include the following:
Figure 1: Common mechanismsinvolved in the pathogenesis of autoinflammatory diseases. NLRP3: Nucleotide oligomerization domain, leucine-rich repeat and pyrin domain containing protein 3, NLRC4: Nucleotide oligomerization domain, leucine-rich repeat caspase activating and recruitment domain domain containing 4, IL-1: Interleukin 1, TNF: Tumour necrosis factor, NF-κB: Nuclear factor kappa light chain enhancer of activated B cells

Click here to view


Type 1 interferonopathies (e.g., Aicardi-Goutières syndrome, STING-associated vasculopathy with onset in infancy, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature)

These group of AIDs are characterized by an increased release of inflammatory mediators secondary to enhanced expression of Type I interferons (IFNs α, β).

Defects affecting the inflammasome (e.g., familial Mediterranean fever, cryopyrin-associated periodic syndrome, hyper IgD syndrome)

In this group of AIDs, there is involvement of the interleukin (IL)-1 pathway. Pro-IL-1 β is cleavedby activated caspase-1through intracellular complexes called inflammasomes. IL-1 β is released by the inflammasomes and this drives the autocatalytic activation of caspase-1.

Noninflammasome-related conditions

  1. TRAPS (e.g., TRAPS)
  2. AID related to IL-1 superfamily receptor antagonists (e.g., deficiency of the interleukin one receptor antagonist)
  3. AID related to ubiquitination defects (e.g., otulipenia)
  4. Nuclear factor-kappa B activation-mediated disorder (e.g., Blau syndrome)
  5. Proteasome-related disorders (e.g., pyogenic arthritis, pyoderma gangrenosum and Acne, proteasome-associated autoinflammatory syndrome)



  Clinical Pointers to an Underlying Autoinflammatory Disease Top


Although the spectrum of clinical manifestations of AIDs is very heterogeneous, there are several clinical pointers to these conditions:

  1. Unexplained, persistent, or recurrent fever-fever patterns in patients with AIDs vary from typically episodic or “periodic” (e.g., FMF) to continuous (e.g., CAPS). Duration of fever often provides valuable clues to the type of disorder
  2. Recurrent systemic manifestations-musculoskeletal (e.g., arthritis) or cutaneous (e.g., rash)
  3. Early onset of symptoms-before the age of 20 years
  4. Significant family history of similar diseases
  5. Persistently elevated laboratory parameters of inflammation during acute attacks.


Before starting laboratory workup for a possible AID, it is essential to rule out other common pediatric disorders (infective, autoimmune, and infiltrative) that can have a similar clinical presentation.

The clinical phenotype of these disorders often provides valuable clues to underlying AID [Table 3] and [Table 4].
Table 3: Classification of autoinflammatory diseases according to their predominant clinical manifestations

Click here to view
Table 4: Clinical phenotypes of commonly encountered autoinflammatory diseases

Click here to view



  Autoinflammatory Diseases Presenting as Predominant Fever Top


Familial Mediterranean fever

Clinical phenotype

Recurrent attacks of febrile illness ranging from 0.5 to 3 days.

Salient features

Cardinal signs and symptoms include peritonitis, arthritis, and pleurisy. Untreated children go on to develop amyloidosis.[4]

Treatment

The mainstay of treatment is colchicine, which is helpful in preventing acute attacks as well as complications (e.g., secondary amyloidosis). In resistant cases, anti-IL1 treatment has been found to be useful.

Hyper IgD syndrome

Clinical phenotype

Characterized by recurrent attacks of febrile illness and a multisystem involvement including gastrointestinal symptoms (e.g., diarrhea, abdominal pain), rash, aphthous ulcers, and arthralgia. These symptoms last 3–6 days.[4]

Salient features

Skin manifestations may include macular, urticarial, or nodular rashes.

Treatment

Acute episodes respond dramatically to corticosteroids. Anti-TNF and anti-IL1 therapies have been tried in severe disease.

Tumor necrosis factor-receptor-associated periodic syndrome

Clinical phenotype

Prolonged attacks of febrile illness with cutaneous, serosal, muscular, synovial oro-cular involvement. These attacks usually last 1–4 weeks and may recur 2–6 times each year.[4]

Salient features

Muscle cramps that migrate in a centrifugal pattern are typical of this disorder. Migrating erythematous rash occurring on extremities is the most common skin manifestation. Ocular inflammation can occur in the form of conjunctivitis or periorbital edema.

Treatment

Acute episodes respond dramatically to corticosteroids. Anti-TNF and anti-IL1 therapies are useful in severe disease.


  Autoinflammatory Diseases Presenting as Fever and Rash (Urticarial) Top


Cryopyrin-associated periodic syndromes

The term CAPS encompasses three diseases: familial cold autoinflammatory syndrome (FCAS); Muckle–Wells syndrome (MWS); neonatal-onset multisystem inflammatory disease (NOMID) that is also known as chronic infantile neurologic cutaneous articular syndrome. All three are associated with variants in NLRP3.[4]

  1. FCAS: It is the mildest variant characterized by cold triggered attacks of fever, urticaria, joint symptoms, and conjunctivitis. The duration of symptoms is usually <2 days
  2. MWS: It has a variable spectrum and may present with fever, rash, arthritis, episcleritis, conjunctivitis, and hearing loss
  3. NOMID: It is the most severe form of CAPS and is characterized by persistent fever, rash, bony overgrowth of the knees, uveitis, optic disc edema, and a variety of the central nervous system manifestations (e.g., headaches, chronic meningitis, and hearing loss).


Treatment

These conditions show a dramatic response to anti-IL1therapy.


  Autoinflammatory Diseases Presenting as Predominant Rash Top


STING-associated vasculopathy with onset in infancy

Clinical phenotype

Clinical features include neonatal onset of severe skin vasculopathy, peripheral gangrene, and interstitial lung disease.[29]

Salient features

An acral rash involving the digits, nose, and earlobes is characteristic. This often results in digital ischemia and autoamputation.

Treatment

Although a variety of immunosuppressive therapies have been tried, none have been found to be effective.

H syndrome

Clinical phenotype

It is characterized by hyperpigmentation, hypertrichosis, heart anomalies, hallux valgus, hepatosplenomegaly, hypogonadism, hearing loss, hyperglycemia, and short stature.[10]

Salient features

Pathognomonic feature is cutaneous hyperpigmentation that typically affects the medial aspect of the thighs.

Treatment

A variety of immunosuppressive therapies have been tried but none have been found to be effective. A few reports suggest that IL-6 blockade with tocilizumab may be beneficial in some cases.[11]

Deficiency of the interleukin thirty-six receptor antagonist

Clinical phenotype

It is characterized by childhood onset of recurrent episodes of high fever and generalized pustular psoriasis.[15]

Salient features

It should be considered in a differential diagnosis of children with generalized pustular psoriasis.

Treatment

Biologics (anti-TNF, anti-IL1) have been tried. Ustekinumab (a monoclonal antibody against the p40 subunit of both IL-12 and IL-23)[44] has been found effective in refractory cases.

Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome

Clinical phenotype

Early-onset recurrent fever, skin involvement (nodular/bullae), myositis, and gradually progressive joint contractures are characteristic.[45]

Salient features

Panniculitis-induced lipodystrophy predominantly in the upper part of the body leading to characteristic thin facies is seen.

Treatment

Oral steroids are effective in treating the inflammation. IFN-targeted drugs are currently being studied.

PLCG2-associated Antibody-deficiency and Immune Dysregulation

Clinical phenotype

Cold induced urticaria with associated recurrent sinopulmonary infections (due to underlying hypogammaglobinemia) is characteristic.[20]

Salient feature

Cutaneous granulomatous lesions develop in severe cases.

Treatment

Replacement monthly intravenous immunoglobulin (IVIg) therapy with cold avoidance, high-dose corticosteroids, and antihistamines has been found effective.

Autoinflammatory PLCG2-associated Antibody deficiency and Immune Dys-regulation

Clinical phenotype

Rash in form of blisters/bullous lesions, enterocolitis, ocular symptoms (e.g., corneal blisters, cataracts, uveitis), musculoskeletal involvement (e.g., arthralgia), and interstitial lung disease is characteristic.[21]

Salient features

Patients have recurrent bacterial and viral sinopulmonary infections due to hypogammaglobinemia.

Treatment

Replacement monthly IVIg along with corticosteroids and anakinra have been tried.

A20 haploinsufficiency

Clinical phenotype

Patients mostly present with recurrent oral, genital, or gastrointestinal ulcers. Other symptoms include recurrent fever, arthralgias, myalgia, arthritis, abdominal pain, rash (acne, cutaneous abscess, pustular rash), and recurrent infections. Ocular manifestations include retinal vasculitis, treatment refractory anterior uveitis, and macular fibrosis. Autoimmune features (e.g., thyroiditis, lupus) may also be prominent.[34],[35]

Salient features

Recurrent oro-genital ulcers are a hallmark of this condition. Some patients may have HLAB51positivity. Differential diagnoses include Behcet's disease and inflammatory bowel disease. Inheritance is autosomal dominant.

Treatment

Colchicine is effective for patients with mild symptoms. For severe disease steroids and biological agents (anti-TNF, anti-IL1, and anti-IL6) can be effective.


  Autoinflammatory Diseases Presenting With Predominant Musculoskeletal System Involvement Top


Chronic/recurrent arthritis

Coatomer-associated protein alpha syndrome

Clinical phenotype

Is characterized by early onset of symptoms (<5 years), pulmonary manifestations (e.g., cough, diffuse alveolar hemorrhage, interstitial lung disease), and musculoskeletal involvement (usually polyarthritis with the involvement of interphalangeal joints of the hands and knees commonly). Glomerular disease (e.g., altered renal function tests, and proteinuria) is seen in the second decade.[31]

Salient feature

Inheritance is autosomal dominant. Most patients (80%) have a positive ANA titer.

Treatment

Arthritis is treated with steroids and disease modifying agents (e.g., methotrexate or azathioprine). For pulmonary hemorrhages, either cyclophosphamide or rituximab can be used. Other immune-modulatory therapies include hydroxychloroquine and IVIg.

Blau syndrome

Clinical phenotype

Triad of uveitis (pan uveitis or chronic intermediate uveitis), skin rash, and musculoskeletal involvement (symmetrical polyarthritis, camptodactyly, and tenosynovitis) is characteristic.[5],[6]

Salient features

The presence of boggy swellings of the joints with uveitis is often pathognomonic.

Treatment

Steroids, disease-modifying agents, methotrexate, adalimumab, and anakinra have been used with variable results.

Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome

Clinical phenotype

Recurrent pyogenic arthritis, cutaneous lesions in form of severe acne, and pyoderma gangrenosum is typical. Other symptoms include aseptic abscesses, pustules, oral ulcers, psoriasis like lesions or suppurative hidradenitis.[7]

Salient features

The [resence of pyoderma gangrenosum with arthritis is a useful pointer to diagnosis.

Treatment

Steroids, cyclosporine, anti-TNF have been tried in this condition.


  Inflammatory Osteolytic Lesions Top


Majeed syndrome

Clinical phenotype

Recurrent episodes of febrile illness, persistent multifocal sterile osteomyelitis, skin involvement (pustulosis, neutrophilic dermatosis), growth failure, and congenital dyserythropoietic anemia are presenting features.[8]

Salient features

Unlike chronic recurrent multifocal osteomyelitis, Majeed syndrome usually starts in early childhood.

Treatment

Therapeutic modalities include non-steroidal anti-inflammatory drugs, corticosteroids, bisphosphonates, and biological drugs (anti-TNF and anti-IL1 therapies).

Deficiency of the interleukin one receptor antagonist

Clinical phenotype

Begins in early infancy and is characterized by skin involvement (e.g., pustular psoriasis-like lesions) and bone (e.g., multifocal sterileosteomyelitis with periostitis involving clavicles, long bones, vertebral bodies, ribs, and hips) involvement.[13]

Salient features

Fever is usually not prominent but the inflammatory markers in serum are high.

Treatment

Rapid clinical response occurs with anti-IL1 therapy, anakinra.


  Autoinflammatory Diseases Presenting With Organ Involvement Top


Deficiency of adenosine deaminase 2

Clinical phenotype

Cardinal features include neurological manifestations (e.g., stroke due to vasculitis), cutaneous involvement (e.g., livedoid rash) and immunodeficiency due to hypogammaglobinemia. Hematological features include pure red cell aplasia, immune thrombocytopenia and hemolytic anemia.[24],[25],[26]

Salient features

The striking neurological feature is stroke. Recurrent infections are noted in 20% of cases. Hypogammaglobulinemia (usually low IgM) is present in 25%. Deficiency of adenosine deaminase 2 has a very variable clinical presentation. It is now considered in the differential diagnosis of children with a variety of clinical conditions including early-onset fevers, rashes, and strokes.

Treatment

Anti-TNF therapy needs to be administered during acute attacks. Patients with symptomatic hypogammaglobulinemia require monthly replacement IVIg therapy.

Aicardi-Goutières syndrome

Clinical phenotypes

Patients with Aicardi-Goutières syndrome (AGS)[1],[2],[3],[4],[29],[43] develop neurological manifestations in form of white matter disease, subacute encephalomyelitis, basal ganglion calcification, developmental delay, and microcephaly. Patients with AGS7 present with developmental delay, spasticity, rash, and arthritis. Patients may have variable rash (e.g., chilblains).[41],[42]

Salient features

Neurological manifestations start in early infancy. As a result, most patients of AGS are followed up in neurology clinics.

Treatment

Treatment is mostly supportive.


  Conclusion Top


AIDs have a wide spectrum of clinical manifestations. It is, therefore, important to identify the broad clinical diagnosis based on clinical features which will further help in narrowing the diagnosis and genetic diagnosis. Hence, it is essential for pediatricians and rheumatologists to be aware of AIDs to make an appropriate diagnosis and the management of patients with AIDs.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.  Back to cited text no. 1
    
2.
French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.  Back to cited text no. 2
    
3.
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.  Back to cited text no. 3
    
4.
Petty RE, Laxer RM, Lindsley CB, Wedderburn LR. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of Pediatric Rheumatology. 7th ed. Ch. 47. Philadelphia: Elsevier; 2016.  Back to cited text no. 4
    
5.
Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-20.  Back to cited text no. 5
    
6.
Rosé CD, Aróstegui JI, Martin TM, Espada G, Scalzi L, Yagüe J, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: Study of an international registry and a national cohort in Spain. Arthritis Rheum 2009;60:1797-803.  Back to cited text no. 6
    
7.
Holzinger D, Roth J. Alarming consequences – Autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1. Curr Opin Rheumatol 2016;28:550-9.  Back to cited text no. 7
    
8.
Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A, et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005;42:551-7.  Back to cited text no. 8
    
9.
Jéru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008;105:1614-9.  Back to cited text no. 9
    
10.
Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: A genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol 2008;59:79-85.  Back to cited text no. 10
    
11.
Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol Online J 2017;15:76.  Back to cited text no. 11
    
12.
Fernandez-Guarino M, Torrelo A, Fernandez-Lorente M, Fraile G, García-Sagredo JM, Jaén P. X-linked reticulate pigmentary disorder: Report of a new family. Eur J Dermatol 2008;18:102-3.  Back to cited text no. 12
    
13.
Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009;360:2426-37.  Back to cited text no. 13
    
14.
Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010;87:866-72.  Back to cited text no. 14
    
15.
Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365:620-8.  Back to cited text no. 15
    
16.
Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y, De Laet C, et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet 2011;43:132-7.  Back to cited text no. 16
    
17.
Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med 2011;365:1502-8.  Back to cited text no. 17
    
18.
Miskinyte S, Nassif A, Merabtene F, Ungeheuer MN, Join-Lambert O, Jais JP, et al. Nicastrin mutations in French families with hidradenitis suppurativa. J Invest Dermatol 2012;132:1728-30.  Back to cited text no. 18
    
19.
Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012;13:1178-86.  Back to cited text no. 19
    
20.
Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012;366:330-8.  Back to cited text no. 20
    
21.
Zhou Q, Lee GS, Brady J, Datta S, Katan M, Sheikh A, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012;91:713-20.  Back to cited text no. 21
    
22.
Fuchs-Telem D, Sarig O, van Steensel MA, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012;91:163-70.  Back to cited text no. 22
    
23.
Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 2013;122:112-23.  Back to cited text no. 23
    
24.
Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921-31.  Back to cited text no. 24
    
25.
Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370:911-20.  Back to cited text no. 25
    
26.
Schepp J, Proietti M, Frede N, Buchta M, Hübscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol 2017;69:1689-700.  Back to cited text no. 26
    
27.
Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu HC, Allen MH, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet 2014;94:790-7.  Back to cited text no. 27
    
28.
Jéru I, Cochet E, Duquesnoy P, Hentgen V, Copin B, Mitjavila-Garcia MT, et al. Brief Report: Involvement of TNFRSF11A molecular defects in autoinflammatory disorders. Arthritis Rheumatol 2014;66:2621-7.  Back to cited text no. 28
    
29.
Crow YJ, Casanova JL. STING-associated vasculopathy with onset in infancy – A new interferonopathy. N Engl J Med 2014;371:568-71.  Back to cited text no. 29
    
30.
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014;46:1140-6.  Back to cited text no. 30
    
31.
Watkin LB, Jessen B, Wiszniewski W, Vece TJ, Jan M, Sha Y, et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 2015;47:654-60.  Back to cited text no. 31
    
32.
Boisson B, Laplantine E, Dobbs K, Cobat A, Tarantino N, Hazen M, et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med 2015;212:939-51.  Back to cited text no. 32
    
33.
Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL, et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci U S A 2016;113:10127-32.  Back to cited text no. 33
    
34.
Aeschlimann FA, Batu ED, Canna SW, Go E, Gül A, Hoffmann P, et al. A20 haploinsufficiency (HA20): Clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis 2018;77:728-35.  Back to cited text no. 34
    
35.
Kadowaki T, Ohnishi H, Kawamoto N, Hori T, Nishimura K, Kobayashi C, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol 2018;141:1485-8.  Back to cited text no. 35
    
36.
Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med 2016;213:1163-74.  Back to cited text no. 36
    
37.
Moghaddas F, Llamas R, De Nardo D, Martinez-Banaclocha H, Martinez-Garcia JJ, Mesa-Del-Castillo P, et al. A novel pyrin-associated autoinflammation with neutrophilic dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to familial mediterranean fever. Ann Rheum Dis 2017;76:2085-94.  Back to cited text no. 37
    
38.
Kuhns DB, Fink DL, Choi U, Sweeney C, Lau K, Priel DL, et al. Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency. Blood 2016;128:2135-43.  Back to cited text no. 38
    
39.
Grandemange S, Sanchez E, Louis-Plence P, Tran Mau-Them F, Bessis D, Coubes C, et al. A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis). Ann Rheum Dis 2017;76:1191-8.  Back to cited text no. 39
    
40.
Göös H, Fogarty CL, Sahu B, Plagnol V, Rajamäki K, Nurmi K, et al. Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy. J Allergy Clin Immunol 2019;144:1364-76.  Back to cited text no. 40
    
41.
Aicardi J, Goutières F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984;15:49-54.  Back to cited text no. 41
    
42.
Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014;46:503-9.  Back to cited text no. 42
    
43.
Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 Update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020;40:24-64.  Back to cited text no. 43
    
44.
Bonekamp N, Caorsi R, Viglizzo GM, Graaf M, Minoia F, Grossi A, et al. High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). Ann Rheum Dis 2018;77:1241-3.  Back to cited text no. 44
    
45.
Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012;64:895-907.  Back to cited text no. 45
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Search Strategy
History
Pathophysiology
Clinical Pointer...
Autoinflammatory...
Autoinflammatory...
Autoinflammatory...
Autoinflammatory...
Inflammatory Ost...
Autoinflammatory...
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed424    
    Printed34    
    Emailed0    
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]